The use of allopurinol in people with chronic kidney disease (CKD) remains one of the most controversial areas in gout management. The aim of this study was to determine the effect of baseline kidney function on safety and efficacy of allopurinol dose escalation to achieve serum urate (SU) <6 mg/dl.
We undertook a post hoc analysis of a 24-month allopurinol dose escalation treat-to-target SU randomized controlled trial, in which 183 people with gout were randomized to continue current dose allopurinol for 12 months and then enter the dose escalation phase or to begin allopurinol dose escalation immediately. Allopurinol was increased monthly until SU was <6 mg/dl. The effect of baseline kidney function on urate lowering and adverse effects was investigated.
Irrespective of randomization, there was no difference in the percentage of those with creatinine clearance (CrCL) <30 ml/min who achieved SU <6 mg/dl at the final visit compared to those with CrCL ≥30 to <60 ml/min and those with CrCL ≥60 ml/min, with percentages of 64.3% vs. 76.4% vs. 75.0%, respectively (p = 0.65). The mean allopurinol dose at month 24 was significantly lower in those with CrCL <30 ml/min as compared to those with CrCL ≥30 to <60 ml/min or CrCL ≥60 ml/min (mean (SD) 250 (43), 365 (22), and 460 (19) mg/day, respectively (p < 0.001)). Adverse events were similar among groups.
Allopurinol is effective at lowering urate even though and accepting that there were small numbers of participants with CrCL <30 ml/min, these data indicate that allopurinol dose escalation to target SU is safe in people with severe CKD. The dose required to achieve target urate is higher in those with better kidney function.
Australian and New Zealand Clinical trials Registry, ACTRN12611000845932. Registered on 10 August 2011.
Khanna D, Fitzgerald J, Khanna P, Sangmee B, Singh M, Neogi T, Pillinger M, Merill J, Lee S, Prakash S, et al. 2012 American College of Rheumatology guidelines for the management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia. Arthritis Care Res. 2012;64(10):1431–46. CrossRef
Stamp L, Day R, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheum. 2016;12(4):235–42. CrossRef
Chung W-H, Chang W-C, Stocker S, Juo C-G, Graham G, Lee M-H, Williams KM, Tian YC, Juan KC, Jan Wu YJ, Yang C-H, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157–64. CrossRefPubMed
Sundy J, Baraf H, Yood R, Edwards N, Gutierrez-Urena S, Treadwell E, Vázquez-Mellado J, White W, Lipsky P, Horowitz Z, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711–20. CrossRefPubMed
Saag K, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker M. Lesinurad combined with allopurinol: randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based study). Arthritis Rheum. 2017;69(1):203–12. CrossRef
Saag K, Whelton A, Becker M, MacDonald P, Hunt B, Gunawardhana L. Impact of febuxostat on renal function in gout subjects with moderate-to-severe renal impairment. Arthritis Rheum. 2016;68(8):2035–43. CrossRef
Vargas-Santos AB, Neogi T. Management of gout and hyperuricaemia in CKD. Am J Kidney Dis. 2017. https://doi.org/10.1053/j.ajkd.2017.01.055.
Becker M, Fitz-Patrick D, Choi H, Dalbeth N, Storgarde C, Cravetsf M, Baumgartner S. An open-label, 6-month study of allopurinol safety in gout: the LASSO study. Semin Arthritis Rheum. 2015;2015(45):174–83. CrossRef
- The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial
Lisa K. Stamp
Peter T. Chapman
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II